Request Demo
Last update 20 Nov 2025
RAY-1225
Last update 20 Nov 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms RAY 002, RAY 1225, RAY-002 + [2] |
Target |
Action agonists |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with RAY-1225NCT07139535
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of RAY1225 Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
NCT07139548
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes
CTR20252928
评价RAY1225注射液对华法林、阿托伐他汀、二甲双胍和地高辛的药代动力学影响研究
[Translation] Evaluation of the effect of RAY1225 injection on the pharmacokinetics of warfarin, atorvastatin, metformin and digoxin
100 Clinical Results associated with RAY-1225
Login to view more data
100 Translational Medicine associated with RAY-1225
Login to view more data
100 Patents (Medical) associated with RAY-1225
Login to view more data
100 Deals associated with RAY-1225
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 3 | China | 22 Aug 2025 | |
| Obesity | Phase 3 | China | 15 Jun 2025 | |
| Metabolic Dysfunction Associated Steatohepatitis | Phase 3 | China | - | |
| Chronic Kidney Diseases | Phase 1 | China | 11 Sep 2024 | |
| Hepatic Insufficiency | Phase 1 | China | 26 Aug 2024 | |
| Liver Injury | Phase 1 | China | 26 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 132 | RAY1225 3mg | eajfidcirv(iswdnwttgt) = ugrllvdrvo rizxkmivwd (kvfcckzkxp, -11.63 to -8.49) | Positive | 20 Jun 2025 | ||
RAY1225 6mg | eajfidcirv(iswdnwttgt) = psmcmbyoyp rizxkmivwd (kvfcckzkxp, -14.51 to -11.43) | ||||||
SHINING-1 (NEWS) Manual  | Phase 2 | - | qjbwdkuftu(esarjglbfk) = zahiymjbqq vdmhbdzqsl (fpsdqlvrkw ) Met View more | Positive | 31 Dec 2024 | ||
qjbwdkuftu(esarjglbfk) = oqxrnjnbkz vdmhbdzqsl (fpsdqlvrkw ) Met View more | |||||||
REBUILDING-1 (NEWS) Manual | Phase 2 | 122 | RAY1225注射液 3mg | bxeexrslij(dwjednfyfo) = jwwuxzakhy dqvqzmclky (antxkilmzf ) View more | Positive | 21 Nov 2024 | |
RAY1225注射液 6mg | bxeexrslij(dwjednfyfo) = hplmdcooox dqvqzmclky (antxkilmzf ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free